MA45656A - Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 - Google Patents

Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1

Info

Publication number
MA45656A
MA45656A MA045656A MA45656A MA45656A MA 45656 A MA45656 A MA 45656A MA 045656 A MA045656 A MA 045656A MA 45656 A MA45656 A MA 45656A MA 45656 A MA45656 A MA 45656A
Authority
MA
Morocco
Prior art keywords
vanin
enzyme inhibitors
new pyrimidine
pyrimidine carboxamides
carboxamides used
Prior art date
Application number
MA045656A
Other languages
English (en)
Inventor
Christophe Philippe Allais
Agustin Casimiro-Garcia
Chulho Choi
David Hepworth
Frank Eldridge Lovering
Joseph Walter Strohbach
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA45656A publication Critical patent/MA45656A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045656A 2016-07-14 2017-07-07 Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 MA45656A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662362098P 2016-07-14 2016-07-14

Publications (1)

Publication Number Publication Date
MA45656A true MA45656A (fr) 2021-03-24

Family

ID=59351004

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045656A MA45656A (fr) 2016-07-14 2017-07-07 Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1

Country Status (14)

Country Link
US (1) US10906888B2 (fr)
EP (1) EP3484876A1 (fr)
JP (1) JP2019524716A (fr)
KR (1) KR20190026902A (fr)
CN (1) CN109476645A (fr)
AU (1) AU2017296338A1 (fr)
BR (1) BR112019000589A2 (fr)
CA (1) CA3030381A1 (fr)
IL (1) IL263662A (fr)
MA (1) MA45656A (fr)
MX (1) MX2019000536A (fr)
RU (1) RU2019100559A (fr)
SG (1) SG11201811161YA (fr)
WO (1) WO2018011681A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
MX394645B (es) 2017-06-12 2025-03-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina.
WO2019133445A1 (fr) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
DK3844161T3 (da) * 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatiske forbindelser som vanininhibitorer.
JP7383696B2 (ja) 2018-09-04 2023-11-20 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての５員～７員の複素環アミド
SG11202104437XA (en) * 2018-12-03 2021-05-28 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors
WO2020114947A1 (fr) 2018-12-03 2020-06-11 Boehringer Ingelheim International Gmbh Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
JP7080405B2 (ja) * 2018-12-03 2022-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング バニン阻害剤としての複素芳香族化合物
CN111388452B (zh) * 2020-04-30 2021-10-26 中国药科大学 脂肪组织靶向肽p3-壳聚糖寡聚乳酸-聚乙二醇递送系统及其在核酸药物递送上的应用
WO2022063197A1 (fr) * 2020-09-25 2022-03-31 上海美悦生物科技发展有限公司 Composé pyrimidine carboxamide et son application
EP4265599A4 (fr) * 2020-12-17 2024-10-23 Shanghai Meiyue Biotech Development Co., Ltd. Composé de pyrimidine carboxamide et son utilisation
JP7607799B2 (ja) * 2021-04-27 2024-12-27 メッドシャイン ディスカバリー インコーポレイテッド ６員芳香族ヘテロ尿素環の誘導体及びその使用
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
JP7802955B2 (ja) * 2022-03-18 2026-01-20 上海美悦生物科技発展有限公司 Ｖａｎｉｎ酵素阻害剤の塩形態、結晶及びその製造方法と使用
CN114933594A (zh) * 2022-07-20 2022-08-23 北京科翔中升医药科技有限公司 一种氟代三嗪类化合物、药物组合物及用途

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508424A (en) 1993-03-26 1996-04-16 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
AU5283800A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
ES2283315T3 (es) 1999-09-16 2007-11-01 Tanabe Seiyaku Co., Ltd. Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico.
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
KR100711042B1 (ko) 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 환상 화합물
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
US6770647B2 (en) 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
WO2003091252A1 (fr) 2002-04-25 2003-11-06 Bristol-Myers Squibb Company Derives d'acide spirobarbiturique utiles en tant qu'inhibiteurs de metalloproteases de matrice (mmp)
RU2326868C2 (ru) 2003-04-28 2008-06-20 Астеллас Фарма Инк. Производное 4,4-дифтор-1,2,2,4-тетрагидро-5н-1-бензазепина или его соль
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
CA2555311A1 (fr) 2004-02-04 2005-08-18 Neurosearch A/S Derives d'aryle diazabicyclique constituant des ligands du recepteur de l'acetylcholine nicotinique
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1950082B (zh) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
CN1972914A (zh) 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
EP1753748B1 (fr) 2004-05-12 2009-07-29 Pfizer Products Inc. Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv
DK1761542T3 (da) 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
CA2581745A1 (fr) 2004-10-13 2006-04-27 Neurogen Corporation Composes de 8-azabicyclo[3.2.1]octane a substitution aryle comme ligands du recepteur de l'hormone de concentration de la melanine
JP4765545B2 (ja) 2004-10-27 2011-09-07 アステラス製薬株式会社 ベンゾアゼピン誘導体を有効成分とする医薬組成物
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
CA2641389A1 (fr) 2006-02-15 2007-08-23 F. Hoffmann-La Roche Ag Composes antiviraux heterocycliques
EP2463283B1 (fr) 2006-04-20 2014-06-11 Pfizer Products Inc. Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase
EP2097420B1 (fr) 2006-11-29 2012-04-04 Pfizer Products Inc. Spirocétone inhibiteurs de la acétyl-coa carboxylase
KR100909953B1 (ko) 2007-06-15 2009-07-31 한국화학연구원 항진균 활성을 갖는 트라이아졸 유도체, 이의 제조방법 및이를 함유하는 약학 조성물
WO2008157552A2 (fr) 2007-06-18 2008-12-24 Mayo Foundation For Medical Education And Research Inhibiteur d'acétylcholinestérase d'invertébrés
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
EP2185537A1 (fr) 2007-08-02 2010-05-19 Pfizer Inc. Dérivés de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions
CA2724603A1 (fr) 2008-05-28 2009-12-03 Pfizer Inc. Inhibiteurs de la pyrazolospirocetone acetyl-coa carboxylase
WO2009144554A1 (fr) 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase
EP2318370A1 (fr) 2008-07-29 2011-05-11 Pfizer Inc. Hétéroaryles fluorés
WO2010020810A1 (fr) 2008-08-19 2010-02-25 Astrazeneca Ab Dérivés de 2-(imidazolylamino)-pyridine et leur utilisation en tant qu'inhibiteurs de la jak kinase
MX2011002166A (es) 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
EP2406230A1 (fr) 2009-03-11 2012-01-18 Pfizer Inc. Indazole amides substitués
WO2010106457A2 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
RU2011143740A (ru) 2009-03-30 2013-05-10 Астеллас Фарма Инк. Соединение пиримидина
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
JP2012526096A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
CA2762680C (fr) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methylsulfanylpyrimidines utiles en tant qu'agents anti-inflammatoires, analgesiques, et anti-epileptiques
KR20120061063A (ko) 2009-06-05 2012-06-12 화이자 인코포레이티드 Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
PH12012502112A1 (en) 2010-04-27 2021-06-23 Mitsubishi Tanabe Pharma Corp Novel amide derivative and use thereof as medicine
CA2800618C (fr) 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Composes heteroaryles et leurs procedes d'utilisation
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
US9193705B2 (en) 2010-09-01 2015-11-24 President And Fellows Of Harvard College Small molecule inhibitors of ebola and lassa fever viruses and methods of use
WO2012068589A2 (fr) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US20140323504A1 (en) 2011-09-20 2014-10-30 Cellzome Limited Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
US20160031813A1 (en) * 2011-11-11 2016-02-04 Michael L. Curtin Nampt Inhibitors
BR112014024552A2 (pt) 2012-04-02 2017-09-19 Cytokinetics Inc método para aprimorar a função do diafragma em um paciente que necessite do mesmo; método para aumentar a função, atividade, eficiência, sensibilidade ao cálcio ou tempo de fadiga do músculo esquelético no diafragma de um paciente que necessite do mesmo e método para aumentar a função, atividade, eficiência, força, sensibilidade ao cálcio ou tempo de fadiga de uma fibra muscular esquelética do diafragma.
EA032480B1 (ru) 2012-04-11 2019-06-28 Сайтокинетикс, Инк. Способы повышения устойчивости скелетных мышц к утомлению
CA2885778A1 (fr) 2012-09-25 2014-04-03 Mathilde Muzerelle Alpha-hydroxy-amides
US9624197B2 (en) 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US10308615B2 (en) * 2015-05-29 2019-06-04 Pfizer Inc. Heterocyclic compounds as inhibitors of Vanin-1 enzyme

Also Published As

Publication number Publication date
US10906888B2 (en) 2021-02-02
MX2019000536A (es) 2019-04-01
EP3484876A1 (fr) 2019-05-22
BR112019000589A2 (pt) 2019-04-24
US20190315715A1 (en) 2019-10-17
WO2018011681A1 (fr) 2018-01-18
RU2019100559A3 (fr) 2020-07-14
SG11201811161YA (en) 2019-01-30
AU2017296338A1 (en) 2019-01-03
JP2019524716A (ja) 2019-09-05
RU2019100559A (ru) 2020-07-14
IL263662A (en) 2019-01-31
KR20190026902A (ko) 2019-03-13
CA3030381A1 (fr) 2018-01-18
CN109476645A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
IL268856A (en) Methods for purification of messenger rna
IL264142A (en) Multispecific antibodies against cd40 and cd137
KR102609396B9 (ko) Ldha의 발현을 억제하기 위한 방법 및 조성물
IL262304A (en) Methods for providing single-stranded rna
CL2018002892A1 (es) Composiciones de conjugado de ácido nucleico dirigido.
EP3555278C0 (fr) Nucléases cas9 thermostables
IL256369A (en) Novel crispr enzymes and systems
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3523437A4 (fr) Compositions d'oligonucléotides et méthodes associées
IL257203B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
EP3518934A4 (fr) Inhibiteurs de l'adénosine 5'-nucléotidase
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3337787A4 (fr) Composés pyrazolo hétérocycliques condensés comme inhibiteurs d'erk
PL3386534T3 (pl) Kompozycje i sposoby internalizacji enzymów
IL263662A (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
PL3387152T3 (pl) Ulepszone adaptory, sposoby i kompozycje do sekwencjonowania dupleksowego
EP3138842A4 (fr) Composés polyfluorés agissant en tant qu'inhibiteurs de la tyrosine kinase de bruton
FR3015187B1 (fr) Utilisation d'une composition renfermant du 1,3-propanediol comme e-liquide
MA41977A (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
EP3374525A4 (fr) Construction haute efficacité de banques d'adn
LT3204015T (lt) Kompozicijos ir būdai, skirti hao1 (hidroksirūgšties oksidazė 1 (glikolato oksidazė)) genų raiškos slopinimui
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
HRP20181698T1 (hr) 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger